HC Wainwright Has Bullish Forecast for Precigen Q1 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright increased their Q1 2026 EPS estimates for Precigen in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of ($0.03) for the quarter, up from their prior estimate of ($0.05). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.02) EPS.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The company had revenue of $4.57 million for the quarter, compared to the consensus estimate of $8.29 million.

A number of other brokerages have also recently issued reports on PGEN. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Wall Street Zen raised Precigen from a “sell” rating to a “hold” rating in a research note on Saturday. Citizens Jmp increased their price target on shares of Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a research report on Thursday. Finally, Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.50.

Precigen Stock Performance

NASDAQ PGEN opened at $3.67 on Monday. The stock has a 50-day simple moving average of $4.08 and a 200 day simple moving average of $3.97. The company has a market capitalization of $1.30 billion, a PE ratio of -2.74 and a beta of 1.10. The company has a current ratio of 3.09, a quick ratio of 2.83 and a debt-to-equity ratio of 4.46. Precigen has a 12 month low of $1.11 and a 12 month high of $5.47.

Institutional Investors Weigh In On Precigen

A number of hedge funds have recently modified their holdings of the business. NBC Securities Inc. acquired a new position in shares of Precigen in the 4th quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in Precigen during the 3rd quarter worth approximately $39,000. Russell Investments Group Ltd. acquired a new stake in Precigen during the 3rd quarter worth approximately $41,000. Mason Investment Advisory Services Inc. bought a new position in Precigen in the fourth quarter valued at approximately $42,000. Finally, Abel Hall LLC acquired a new position in shares of Precigen in the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.